[Federal Register Volume 82, Number 47 (Monday, March 13, 2017)]
[Notices]
[Page 13461]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-04808]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Nicotinic Immune Modulation in the Presence of HIV-1 
Infection (R01).
    Date: March 22, 2017.
    Time: 11:00 a.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Shang-Yi Anne Tsai, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4228, MSC 9550, Bethesda, MD 20892, 
301-827-5842, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; HIV, HCV and Related Comorbidities in Rural 
Communities Affected by Opioid Injection Drug Epidemics in the 
United States: Building Systems for Prevention, Treatment and 
Control (UG3/UH3).
    Date: March 24, 2017.
    Time: 8:00 a.m. to 12:00 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: Courtyard by Marriott Chevy Chase, 5520 Wisconsin Avenue, 
Chevy Chase, MD 20815.
    Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, 
Office of Extramural Policy and Review, National Institute on Drug 
Abuse, National Institutes of Health, DHHS, 6001 Executive 
Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820, 
[email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Hepatitis C Virus (HCV) Advanced Molecular Detection 
in Support of Systems for Prevention, Treatment and Control of HIV, 
HCV and Related Comorbidities in Rural Communities Affected by 
Opioid Injection Drug Epidemics in the Unite.
    Date: March 24, 2017.
    Time: 12:30 p.m. to 5:00 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: Courtyard by Marriott Chevy Chase, 5520 Wisconsin Avenue, 
Chevy Chase, MD 20815.
    Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, 
Office of Extramural Policy and Review, National Institute on Drug 
Abuse, National Institutes of Health, DHHS, 6001 Executive 
Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820, 
[email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; 2017 Loan Repayment.
    Date: March 26, 2017.
    Time: 10:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
    Contact Person: Lyle Furr, Scientific Review Officer, Office of 
Extramural Policy and Review, National Institute on Drug Abuse, NIH, 
DHHS, Room 4227, MSC 9550, 6001 Executive Boulevard, Bethesda, MD 
20892-9550, 301-827-5702, lf33c.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: March 7, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-04808 Filed 3-10-17; 8:45 am]
 BILLING CODE 4140-01-P